{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:09:35Z","timestamp":1789985375540,"version":"4.0.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T00:00:00Z","timestamp":1547596800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13148-018-0600-2","type":"journal-article","created":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T08:02:58Z","timestamp":1547625778000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Demethylation by low-dose 5-aza-2\u2032-deoxycytidine impairs 3D melanoma invasion partially through miR-199a-3p expression revealing the role of this miR in melanoma"],"prefix":"10.1186","volume":"11","author":[{"given":"C\u00e9cile","family":"Desjobert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Carrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Delmas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego M.","family":"Marzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Daunay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Busato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Pillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Tost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Riond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Favre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Etievant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5175-4396","authenticated-orcid":false,"given":"Paola B.","family":"Arimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,16]]},"reference":[{"issue":"6","key":"600_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrc.2016.37","volume":"16","author":"AH Shain","year":"2016","unstructured":"Shain AH, Bastian BC. From melanocytes to melanomas. Nat Rev Cancer. 2016;16(6):345\u201358.","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"600_CR2","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/imj.13574","volume":"47","author":"V Atkinson","year":"2017","unstructured":"Atkinson V. Recent advances in malignant melanoma. Intern Med J. 2017;47(10):1114\u201321.","journal-title":"Intern Med J"},{"issue":"5","key":"600_CR3","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nrclinonc.2013.42","volume":"10","author":"N Azad","year":"2013","unstructured":"Azad N, Zahnow CA, Rudin CM, Baylin SB. The future of epigenetic therapy in solid tumours--lessons from the past. Nat Rev Clin Oncol. 2013;10(5):256\u201366.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"600_CR4","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1755-148X.2011.00828.x","volume":"24","author":"K Conway","year":"2011","unstructured":"Conway K, Edmiston SN, Khondker ZS, Groben PA, Zhou X, Chu H, et al. DNA-methylation profiling distinguishes malignant melanomas from benign nevi. Pigment Cell Melanoma Res. 2011;24(2):352\u201360.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"600_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/1479-5876-10-185","volume":"10","author":"L Sigalotti","year":"2012","unstructured":"Sigalotti L, Covre A, Fratta E, Parisi G, Sonego P, Colizzi F, et al. Whole genome methylation profiles as independent markers of survival in stage iiic melanoma patients. J Transl Med. 2012;10(1):185.","journal-title":"J Transl Med"},{"issue":"8","key":"600_CR6","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1101\/gr.091447.109","volume":"19","author":"Y Koga","year":"2009","unstructured":"Koga Y, Pelizzola M, Cheng E, Krauthammer M, Sznol M, Ariyan S, et al. Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res. 2009;19(8):1462\u201370.","journal-title":"Genome Res"},{"issue":"1","key":"600_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/hmg\/ddt420","volume":"23","author":"DM Marzese","year":"2014","unstructured":"Marzese DM, Scolyer RA, Huynh JL, Huang SK, Hirose H, Chong KK, et al. Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Hum Mol Genet. 2014;23(1):226\u201338.","journal-title":"Hum Mol Genet"},{"issue":"5","key":"600_CR8","doi-asserted-by":"publisher","first-page":"e96612","DOI":"10.1371\/journal.pone.0096612","volume":"9","author":"S Ecsedi","year":"2014","unstructured":"Ecsedi S, Hernandez-Vargas H, Lima SC, Vizkeleti L, Toth R, Lazar V, et al. DNA methylation characteristics of primary melanomas with distinct biological behaviour. PLoS One. 2014;9(5):e96612.","journal-title":"PLoS One"},{"key":"600_CR9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.semcancer.2017.10.006","volume":"51","author":"B Moran","year":"2018","unstructured":"Moran B, Silva R, Perry AS, Gallagher WM. Epigenetics of malignant melanoma. Semin Cancer Biol. 2018;51:80\u20138.","journal-title":"Semin Cancer Biol"},{"key":"600_CR10","doi-asserted-by":"crossref","unstructured":"Besaratinia A, Tommasi S. Epigenetics of human melanoma: promises and challenges. J Mol Cell Biol. 2014.","DOI":"10.1093\/jmcb\/mju027"},{"issue":"3","key":"600_CR11","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/CMR.0b013e32832b274e","volume":"19","author":"CS Tellez","year":"2009","unstructured":"Tellez CS, Shen L, Estecio MR, Jelinek J, Gershenwald JE, Issa JP. CpG island methylation profiling in human melanoma cell lines. Melanoma Res. 2009;19(3):146\u201355.","journal-title":"Melanoma Res"},{"issue":"1","key":"600_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/gcc.20615","volume":"48","author":"VF Bonazzi","year":"2009","unstructured":"Bonazzi VF, Irwin D, Hayward NK. Identification of candidate tumor suppressor genes inactivated by promoter methylation in melanoma. Genes, chromosomes & cancer. 2009;48(1):10\u201321.","journal-title":"Genes, chromosomes & cancer"},{"issue":"6","key":"600_CR13","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ygeno.2015.09.004","volume":"106","author":"SG Jin","year":"2015","unstructured":"Jin SG, Xiong W, Wu X, Yang L, Pfeifer GP. The DNA methylation landscape of human melanoma. Genomics. 2015;106(6):322\u201330.","journal-title":"Genomics"},{"issue":"6","key":"600_CR14","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/pcmr.12289","volume":"27","author":"NE Thomas","year":"2014","unstructured":"Thomas NE, Slater NA, Edmiston SN, Zhou X, Kuan PF, Groben PA, et al. DNA methylation profiles in primary cutaneous melanomas are associated with clinically significant pathologic features. Pigment Cell Melanoma Res. 2014;27(6):1097\u2013105.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"5","key":"600_CR15","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1158\/1078-0432.CCR-08-1361","volume":"15","author":"A Tanemura","year":"2009","unstructured":"Tanemura A, Terando AM, Sim MS, van Hoesel AQ, de Maat MF, Morton DL, et al. CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res. 2009;15(5):1801\u20137.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"600_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/15592294.2014.1003746","volume":"10","author":"D Sarkar","year":"2015","unstructured":"Sarkar D, Leung EY, Baguley BC, Finlay GJ, Askarian-Amiri ME. Epigenetic regulation in human melanoma: past and future. Epigenetics. 2015;10(2):103\u201321.","journal-title":"Epigenetics"},{"key":"600_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13148-017-0332-8","volume":"9","author":"G Micevic","year":"2017","unstructured":"Micevic G, Theodosakis N, Bosenberg M. Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities. Clin Epigenetics. 2017;9:34.","journal-title":"Clin Epigenetics"},{"key":"600_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1479-5876-8-56","volume":"8","author":"L Sigalotti","year":"2010","unstructured":"Sigalotti L, Covre A, Fratta E, Parisi G, Colizzi F, Rizzo A, et al. Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J Transl Med. 2010;8:56.","journal-title":"J Transl Med"},{"issue":"10","key":"600_CR19","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1158\/0008-5472.CAN-09-4512","volume":"70","author":"D Philippidou","year":"2010","unstructured":"Philippidou D, Schmitt M, Moser D, Margue C, Nazarov PV, Muller A, et al. Signatures of microRNAs and selected microRNA target genes in human melanoma. Cancer Res. 2010;70(10):4163\u201373.","journal-title":"Cancer Res"},{"issue":"33","key":"600_CR20","doi-asserted-by":"publisher","first-page":"5246","DOI":"10.2174\/1381612820666140128210105","volume":"20","author":"E Greenberg","year":"2014","unstructured":"Greenberg E, Nemlich Y, Markel G. MicroRNAs in cancer: lessons from melanoma. Curr Pharm Des. 2014;20(33):5246\u201359.","journal-title":"Curr Pharm Des"},{"key":"600_CR21","doi-asserted-by":"publisher","first-page":"634749","DOI":"10.1155\/2015\/634749","volume":"2015","author":"CR Gasque Schoof","year":"2015","unstructured":"Gasque Schoof CR, Izzotti A, Jasiulionis MG, Vasques Ldos R. The roles of miR-26, miR-29, and miR-203 in the silencing of the epigenetic machinery during melanocyte transformation. Biomed Res Int. 2015;2015:634749.","journal-title":"Biomed Res Int"},{"issue":"1","key":"600_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/ijc.26320","volume":"131","author":"O Alcazar","year":"2012","unstructured":"Alcazar O, Achberger S, Aldrich W, Hu Z, Negrotto S, Saunthararajah Y, et al. Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo. Int J Cancer J Int du cancer. 2012;131(1):18\u201329.","journal-title":"Int J Cancer J Int du cancer"},{"issue":"10","key":"600_CR23","doi-asserted-by":"publisher","first-page":"6178","DOI":"10.1167\/iovs.14-13933","volume":"55","author":"F Rajaii","year":"2014","unstructured":"Rajaii F, Asnaghi L, Enke R, Merbs SL, Handa JT, Eberhart CG. The demethylating agent 5-AZA reduces the growth, invasiveness, and clonogenicity of uveal and cutaneous melanoma. Invest Ophthalmol Vis Sci. 2014;55(10):6178\u201386.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"600_CR24","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.canlet.2015.08.023","volume":"369","author":"S Noguchi","year":"2015","unstructured":"Noguchi S, Mori T, Igase M, Mizuno T. A novel apoptosis-inducing mechanism of 5-aza-2\u2032-deoxycitidine in melanoma cells: demethylation of TNF-alpha and activation of FOXO1. Cancer Lett. 2015;369(2):344\u201353.","journal-title":"Cancer Lett"},{"issue":"1","key":"600_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jid.2016.08.024","volume":"137","author":"V Lucarini","year":"2017","unstructured":"Lucarini V, Buccione C, Ziccheddu G, Peschiaroli F, Sestili P, Puglisi R, et al. Combining type I interferons and 5-aza-2\u2032-deoxycitidine to improve anti-tumor response against melanoma. J Invest Dermatol. 2017;137(1):159\u201369.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"600_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jbiotec.2010.01.012","volume":"148","author":"F Hirschhaeuser","year":"2010","unstructured":"Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA. Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol. 2010;148(1):3\u201315.","journal-title":"J Biotechnol"},{"issue":"3","key":"600_CR27","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.ccr.2011.12.029","volume":"21","author":"HC Tsai","year":"2012","unstructured":"Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 2012;21(3):430\u201346.","journal-title":"Cancer Cell"},{"issue":"21","key":"600_CR28","doi-asserted-by":"publisher","first-page":"6823","DOI":"10.1093\/nar\/gki987","volume":"33","author":"DJ Weisenberger","year":"2005","unstructured":"Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, Fiala E, et al. Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res. 2005;33(21):6823\u201336.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"600_CR29","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1755-148X.2011.00857.x","volume":"24","author":"L Levati","year":"2011","unstructured":"Levati L, Pagani E, Romani S, Castiglia D, Piccinni E, Covaciu C, et al. MicroRNA-155 targets the SKI gene in human melanoma cell lines. Pigment Cell Melanoma Res. 2011;24(3):538\u201350.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"24","key":"600_CR30","doi-asserted-by":"publisher","first-page":"10128","DOI":"10.1158\/0008-5472.CAN-08-2148","volume":"68","author":"C Migliore","year":"2008","unstructured":"Migliore C, Petrelli A, Ghiso E, Corso S, Capparuccia L, Eramo A, et al. MicroRNAs impair MET-mediated invasive growth. Cancer Res. 2008;68(24):10128\u201336.","journal-title":"Cancer Res"},{"issue":"7","key":"600_CR31","doi-asserted-by":"publisher","first-page":"8449","DOI":"10.3390\/ijms13078449","volume":"13","author":"S Gu","year":"2012","unstructured":"Gu S, Chan WY. Flexible and versatile as a chameleon-sophisticated functions of microRNA-199a. Int J Mol Sci. 2012;13(7):8449\u201366.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"600_CR32","first-page":"393","volume":"35","author":"L Levati","year":"2009","unstructured":"Levati L, Alvino E, Pagani E, Arcelli D, Caporaso P, Bondanza S, et al. Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotic activity of miRNA-155. Int J Oncol. 2009;35(2):393\u2013400.","journal-title":"Int J Oncol"},{"issue":"1","key":"600_CR33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"d W Huang","year":"2009","unstructured":"Huang d W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44\u201357.","journal-title":"Nat Protoc"},{"issue":"2","key":"600_CR34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/CMR.0b013e32835e7734","volume":"23","author":"AM Minisini","year":"2013","unstructured":"Minisini AM, Pascoletti G, Intersimone D, Poletto E, Driol P, Spizzo R, et al. Expression of thymidine phosphorylase and cyclooxygenase-2 in melanoma. Melanoma Res. 2013;23(2):96\u2013101.","journal-title":"Melanoma Res"},{"issue":"2","key":"600_CR35","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1200\/JCO.2005.01.5180","volume":"24","author":"IM Bachmann","year":"2006","unstructured":"Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 2006;24(2):268\u201373.","journal-title":"J Clin Oncol"},{"issue":"2","key":"600_CR36","doi-asserted-by":"publisher","first-page":"286","DOI":"10.4161\/cc.11.2.18707","volume":"11","author":"P Hou","year":"2012","unstructured":"Hou P, Liu D, Dong J, Xing M. The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells. Cell Cycle. 2012;11(2):286\u201395.","journal-title":"Cell Cycle"},{"key":"600_CR37","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/1476-4598-9-271","volume":"9","author":"S Bergeron","year":"2010","unstructured":"Bergeron S, Lemieux E, Durand V, Cagnol S, Carrier JC, Lussier JG, et al. The serine protease inhibitor serpinE2 is a novel target of ERK signaling involved in human colorectal tumorigenesis. Mol Cancer. 2010;9:271.","journal-title":"Mol Cancer"},{"issue":"4","key":"600_CR38","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1093\/annonc\/mds591","volume":"24","author":"HA Tawbi","year":"2013","unstructured":"Tawbi HA, Beumer JH, Tarhini AA, Moschos S, Buch SC, Egorin MJ, et al. Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I\/II study and pharmacokinetic analysis. Ann Oncol. 2013;24(4):1112\u20139.","journal-title":"Ann Oncol"},{"issue":"51","key":"600_CR39","doi-asserted-by":"publisher","first-page":"89182","DOI":"10.18632\/oncotarget.21269","volume":"8","author":"Y Zakharia","year":"2017","unstructured":"Zakharia Y, Monga V, Swami U, Bossler AD, Freesmeier M, Frees M, et al. Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: a phase lb study. Oncotarget. 2017;8(51):89182\u201393.","journal-title":"Oncotarget"},{"issue":"2","key":"600_CR40","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.canlet.2012.01.020","volume":"342","author":"ES Greenberg","year":"2014","unstructured":"Greenberg ES, Chong KK, Huynh KT, Tanaka R, Hoon DS. Epigenetic biomarkers in skin cancer. Cancer Lett. 2014;342(2):170\u20137.","journal-title":"Cancer Lett"},{"issue":"2","key":"600_CR41","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/bjd.12989","volume":"171","author":"V Sun","year":"2014","unstructured":"Sun V, Zhou WB, Majid S, Kashani-Sabet M, Dar AA. MicroRNA-mediated regulation of melanoma. Br J Dermatol. 2014;171(2):234\u201341.","journal-title":"Br J Dermatol"},{"issue":"1","key":"600_CR42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1868-7083-5-3","volume":"5","author":"M Karahoca","year":"2013","unstructured":"Karahoca M, Momparler RL. Pharmacokinetic and pharmacodynamic analysis of 5-aza-2\u2032-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. Clin Epigenetics. 2013;5(1):3.","journal-title":"Clin Epigenetics"},{"issue":"5","key":"600_CR43","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.cell.2012.10.028","volume":"151","author":"N Pencheva","year":"2012","unstructured":"Pencheva N, Tran H, Buss C, Huh D, Drobnjak M, Busam K, et al. Convergent multi-miRNA targeting of ApoE drives LRP1\/LRP8-dependent melanoma metastasis and angiogenesis. Cell. 2012;151(5):1068\u201382.","journal-title":"Cell"},{"issue":"6","key":"600_CR44","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.3892\/mmr.2016.5202","volume":"13","author":"X Yang","year":"2016","unstructured":"Yang X, Lei S, Long J, Liu X, Wu Q. MicroRNA-199a-5p inhibits tumor proliferation in melanoma by mediating HIF-1alpha. Mol Med Rep. 2016;13(6):5241\u20137.","journal-title":"Mol Med Rep"},{"issue":"31","key":"600_CR45","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1038\/onc.2011.60","volume":"30","author":"HH Cheung","year":"2011","unstructured":"Cheung HH, Davis AJ, Lee TL, Pang AL, Nagrani S, Rennert OM, et al. Methylation of an intronic region regulates miR-199a in testicular tumor malignancy. Oncogene. 2011;30(31):3404\u201315.","journal-title":"Oncogene"},{"issue":"25","key":"600_CR46","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1038\/onc.2011.13","volume":"30","author":"G Mudduluru","year":"2011","unstructured":"Mudduluru G, Ceppi P, Kumarswamy R, Scagliotti GV, Papotti M, Allgayer H. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a\/b in solid cancer. Oncogene. 2011;30(25):2888\u201399.","journal-title":"Oncogene"},{"issue":"9","key":"600_CR47","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.18632\/oncotarget.1830","volume":"5","author":"E Minna","year":"2014","unstructured":"Minna E, Romeo P, De Cecco L, Dugo M, Cassinelli G, Pilotti S, et al. miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma. Oncotarget. 2014;5(9):2513\u201328.","journal-title":"Oncotarget"},{"issue":"6","key":"600_CR48","doi-asserted-by":"publisher","first-page":"5833","DOI":"10.1007\/s13277-014-1774-7","volume":"35","author":"J Huang","year":"2014","unstructured":"Huang J, Dong B, Zhang J, Kong W, Chen Y, Xue W, et al. miR-199a-3p inhibits hepatocyte growth factor\/c-met signaling in renal cancer carcinoma. Tumour Biol. 2014;35(6):5833\u201343.","journal-title":"Tumour Biol"},{"issue":"7","key":"600_CR49","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1097\/IGC.0b013e31829ea779","volume":"23","author":"D Wu","year":"2013","unstructured":"Wu D, Huang HJ, He CN, Wang KY. MicroRNA-199a-3p regulates endometrial cancer cell proliferation by targeting mammalian target of rapamycin (mTOR). Int J Gynecol Cancer. 2013;23(7):1191\u20137.","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"600_CR50","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.ajpath.2014.01.017","volume":"184","author":"Y Qu","year":"2014","unstructured":"Qu Y, Huang X, Li Z, Liu J, Wu J, Chen D, et al. miR-199a-3p inhibits aurora kinase a and attenuates prostate cancer growth: new avenue for prostate cancer treatment. Am J Pathol. 2014;184(5):1541\u20139.","journal-title":"Am J Pathol"},{"issue":"11","key":"600_CR51","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1093\/neuonc\/nou107","volume":"16","author":"DM Marzese","year":"2014","unstructured":"Marzese DM, Scolyer RA, Roque M, Vargas-Roig LM, Huynh JL, Wilmott JS, et al. DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. Neuro-Oncology. 2014;16(11):1499\u2013509.","journal-title":"Neuro-Oncology"},{"issue":"9","key":"600_CR52","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1038\/nprot.2007.314","volume":"2","author":"J Tost","year":"2007","unstructured":"Tost J, Gut IG. DNA methylation analysis by pyrosequencing. Nat Protoc. 2007;2(9):2265\u201375.","journal-title":"Nat Protoc"},{"issue":"7","key":"600_CR53","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/sim.4780090710","volume":"9","author":"Y Hochberg","year":"1990","unstructured":"Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med. 1990;9(7):811\u20138.","journal-title":"Stat Med"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-018-0600-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13148-018-0600-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-018-0600-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T19:04:20Z","timestamp":1579115060000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-018-0600-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,16]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["600"],"URL":"https:\/\/doi.org\/10.1186\/s13148-018-0600-2","relation":{},"ISSN":["1868-7075","1868-7083"],"issn-type":[{"value":"1868-7075","type":"print"},{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,16]]},"assertion":[{"value":"4 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed consent was obtained from all subjects, and experiments were performed according to the principles set out in the WMA Declaration of Helsinki and the NIH Belmont Report. Tissue specimens were coded according to HIPAA recommendations to ensure the confidentiality of the patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"9"}}